- Record: found
- Abstract: found
- Article: not found
Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome.
C M Legendre
1 ,
C Licht ,
P Muus ,
L A Greenbaum ,
S Babu ,
C Bedrosian ,
C Bingham ,
D J Cohen ,
Y Delmas ,
K Douglas ,
F Eitner ,
T Feldkamp ,
D Fouque ,
R R Furman ,
O Gaber ,
M Herthelius ,
M Hourmant ,
D Karpman ,
Y Lebranchu ,
C Mariat ,
J Menne ,
B Moulin ,
J Nürnberger ,
M Ogawa ,
G Remuzzi ,
T Richard ,
R Sberro-Soussan ,
B Severino ,
N S Sheerin ,
A Trivelli ,
L B Zimmerhackl ,
T Goodship ,
C Loirat
Jun 06 2013
Read this article at
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Atypical hemolytic-uremic syndrome is a genetic, life-threatening, chronic disease of complement-mediated thrombotic microangiopathy. Plasma exchange or infusion may transiently maintain normal levels of hematologic measures but does not treat the underlying systemic disease.